International Journal of Clinical Oncology最新文献

{"title":"The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study.","authors":"Tao Huang, Zhimin Fan, Yongsheng Wang, Xi Yan, Hongjian Yang, Shu Wang, Da Pang, Huiping Li, Haibo Wang, Cuizhi Geng, Liang Huang, Yaqing Sun, Bei Wang, Guofang Sun, Asna Siddiqui, Eleonora Restuccia, Zhimin Shao","doi":"10.1007/s10147-025-02935-7","DOIUrl":"https://doi.org/10.1007/s10147-025-02935-7","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) demonstrated non-inferior cycle 7 pertuzumab and trastuzumab serum trough concentrations (C_trough), and similar total pathological complete response (tpCR) rates and safety, to intravenous pertuzumab plus trastuzumab (P + H IV) in HER2-positive early breast cancer (eBC). In the FDChina study (NCT04024462), we assessed neoadjuvant-adjuvant PH FDC SC vs. P + H IV in Chinese patients with HER2-positive eBC.</p><p><strong>Methods: </strong>Patients received four doxorubicin (60 mg/m²) plus cyclophosphamide (600 mg/m²), then four docetaxel (75-100 mg/m²) cycles, every 3 weeks. Patients were randomized 1:1 to PH FDC SC (loading: 1200 mg pertuzumab/600 mg trastuzumab; maintenance: 600 mg/600 mg) or P + H IV (loading: 840 mg/8 mg/kg; maintenance: 420 mg/6 mg/kg) alongside docetaxel before surgery. Patients then continued HER2-targeted therapy for 14 cycles. Co-primary non-inferiority endpoints: cycle 7 pertuzumab and trastuzumab C_trough. Secondary endpoints: tpCR, long-term efficacy, safety.</p><p><strong>Results: </strong>The lower bounds of the 90% confidence intervals of pertuzumab and trastuzumab cycle 7 geometric mean ratios (0.99 and 1.44, respectively) exceeded the pre-specified non-inferiority margin (0.8). tpCR rates were 55.6% for PH FDC SC vs. 56.4% for P + H IV. Grade ≥ 3 adverse events occurred in 72% vs. 69% of patients.</p><p><strong>Conclusion: </strong>The study met the co-primary endpoints of non-inferiority of cycle 7 serum C_trough for pertuzumab and trastuzumab for PH FDC SC vs. P + H IV. tpCR rates and safety were comparable between arms. PH FDC SC may be a viable treatment option for Chinese patients with HER2-positive eBC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival outcomes of the patients with advanced laryngeal squamous cell carcinoma treated with chemoradiotherapy and total laryngectomy based on reports of head and neck cancer registry of Japan.","authors":"Yuta Yamamura, Yuto Horichi, Tatsuya Furukawa, Hirotaka Shinomiya, Megumi Kitayama, Daisuke Kawakita, Takeshi Kodaira, Munenaga Nakamizo, Seiichi Yoshimoto, Ken-Ichi Nibu","doi":"10.1007/s10147-025-02938-4","DOIUrl":"https://doi.org/10.1007/s10147-025-02938-4","url":null,"abstract":"<p><strong>Background: </strong>Roles of induction chemotherapy (ICT) and chemoradiotherapy (CRT) for laryngeal preservation in patients with locally advanced laryngeal cancer (LC) remain unclear.</p><p><strong>Patients and methods: </strong>We enrolled 834 patients with T3N0-2M0 and T4aN0-2M0 LC registered in the Head and Neck Cancer Registry of Japan between 2011 and 2015. Oncological outcomes of total laryngectomy (TL), CRT, and ICT were evaluated. Propensity score-matching analyses (PSMA) were performed between TL and CRT, excluding ICT.</p><p><strong>Results: </strong>No significant differences were observed in overall survival (OS) and disease-specific survival (DSS) among patients treated by TL, CRT, and ICT followed by TL or CRT, and among patients treated by TL and CRT in PSMA. Of note, no significant difference was observed in LCR and LRFS between TL and ICT groups.</p><p><strong>Conclusions: </strong>ICT and CRT did not yield survival benefits but might contribute to laryngeal preservation without compromising survival in patients with T3-4aN0-2M0.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide genomic data analysis of central nervous system tumors in Japan based on C-CAT database.","authors":"Daisuke Kawauchi, Makoto Ohno, Masamichi Takahashi, Takafumi Koyama, Kuniko Sunami, Makoto Hirata, Shunsuke Yanagisawa, Takaki Omura, Takuma Aoki, Genta Fujii, Koji Saito, Tetsuya Yamamoto, Hiromichi Suzuki, Yoshitaka Narita","doi":"10.1007/s10147-026-03031-0","DOIUrl":"https://doi.org/10.1007/s10147-026-03031-0","url":null,"abstract":"<p><strong>Background: </strong>Comprehensive genomic profiling test (CGPT) using next-generation sequencing (NGS) plays a vital role in cancer diagnosis, treatment option, and prognostic evaluation. In Japan, three tissue-based CGPTs, FoundationOne® CDx, GenMineTOP, and NCC OncoGuide™, are reimbursed under public health insurance. However, their comparative performance in central nervous system (CNS) tumors remains unclear.</p><p><strong>Methods: </strong>We conducted a nationwide, retrospective analysis using data from the Center for Cancer Genomics and Advanced Therapeutics database. A total of 1,151 patients with CNS tumors who underwent CGPT between August 2023 and April 2025 were included. Patient characteristics, genetic mutations, tumor mutation burden, and numbers of drug and clinical trial suggestions were compared across the three CGPTs.</p><p><strong>Results: </strong>FoundationOne® CDx detected significantly more mutations and copy number alterations than GenMineTOP and NCC OncoGuide. It also proposed more off-label drugs and domestic clinical trials. Conversely, GenMineTOP demonstrated the highest detection rate of gene fusions (9.6%), including KIAA1549-BRAF, FGFR3-TACC3, and EGFR-SEPT14, and PTPRZ1-MET. Furthermore, GenMineTOP identified germline mutations in 4.6% of patients, commonly involving TP53, BRCA2, and MSH6.</p><p><strong>Conclusion: </strong>FoundationOne® CDx exhibits greater number of mutations, copy number alterations, and generating therapeutic suggestions, while GenMineTOP excels in identifying fusion genes and germline variants. These findings underscore that each CGPT possesses distinct analytical strengths, and the choice of platform may influence the genomic landscape and therapeutic opportunities identified in CNS tumor patients.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the management and prognosis of mucinous borderline ovarian tumors: analysis of 12,766 cases from the JSOG Gynecologic Tumor Registry (2004-2018).","authors":"Hideki Tokunaga, Yusuke Shibuya, Wataru Yamagami, Fumiaki Takahashi, Eiko Yamamoto, Yoshihito Yokoyama, Kiyoshi Yoshino, Kei Kawana, Satoru Nagase","doi":"10.1007/s10147-026-03008-z","DOIUrl":"10.1007/s10147-026-03008-z","url":null,"abstract":"<p><strong>Background: </strong>Mucinous borderline ovarian tumors (MBOTs) are rare neoplasms with excellent prognosis, yet the optimal surgical extent remains controversial. No large-scale study in Japan has evaluated treatment trends and prognostic factors for MBOTs. This study aimed to clarify their clinicopathological features, management patterns, and survival outcomes using a nationwide registry.</p><p><strong>Methods: </strong>Data were obtained from the Japan Society of Obstetrics and Gynecology Gynecologic Tumor Registry, including 96,476 ovarian tumors treated between 2004 and 2018. Among them, 12,766 MBOT cases were identified. Surgical procedures-hysterectomy, omentectomy, lymphadenectomy, and adjuvant chemotherapy-were analyzed. Survival analyses of 8564 cases with complete prognostic data were performed using Kaplan-Meier and Cox proportional hazards models.</p><p><strong>Results: </strong>Over 90% of MBOTs were stage I, and the median age was 52 years. Hysterectomy was performed in 50.8%, omentectomy in 57.9% (2015-2018 subset), and lymphadenectomy in 7.6%. Only 2.6% received adjuvant chemotherapy. The 5-year overall survival exceeded 95%. Multivariate analysis identified age ≥ 50 years (HR 2.5, 95% CI 1.8-3.6) and stage IC (HR 2.7, 95% CI 1.9-3.6) as independent adverse factors. Omentectomy showed a marginal survival benefit (HR 0.6, p = 0.05), whereas hysterectomy, lymphadenectomy, and chemotherapy conferred no advantage. Chemotherapy correlated with poorer outcomes, likely due to confounding by indication.</p><p><strong>Conclusions: </strong>This nationwide cohort-the largest MBOT series reported to date-demonstrates conservative management with excellent prognosis in Japan. Radical surgery and chemotherapy provide no survival benefit, whereas fertility-sparing surgery appears appropriate for younger patients.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"785-793"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative genomic landscape of primary and metastatic bladder urothelial carcinoma in a large-scale cohort.","authors":"Akira Ohtsu, Yusuke Otani, Seiji Arai, Anna Rogachevskaya, Vanessa D Chin, Shinichi Toyooka, Kazuhiro Suzuki, Wenyi Wei, Atsushi Tanaka","doi":"10.1007/s10147-026-03005-2","DOIUrl":"10.1007/s10147-026-03005-2","url":null,"abstract":"<p><strong>Background: </strong>Metastatic bladder urothelial carcinoma has poor survival, and large comparative genomic studies using uniform targeted sequencing of paired primary and metastatic lesions remain limited. We compared gene- and pathway-level alterations between primary and metastatic tumors METHODS: We analyzed 2,880 bladder urothelial carcinoma samples (2,305 primary; 575 metastatic) from 2,343 patients profiled with MSK-IMPACT. Somatic mutations and copy number alterations were integrated per gene and compared between primary and metastatic samples in the full cohort and in a paired subset using standard statistical tests.</p><p><strong>Results: </strong>Primary and metastatic samples showed broadly similar driver landscapes. In the full cohort, KDM6A, FGFR3, STAG2, and ERCC2 were more frequently altered in primary tumors, whereas no individual genes were enriched in metastases; these differences were not significant in paired analyses. At the pathway level, TP53 pathway alterations were relatively more frequent in metastases, while DNA damage response alterations were enriched in primary tumors; other pathways showed comparable alteration rates. Apoptosis-focused analyses identified no significant gene-level differences, but suggested a trend toward higher alteration rates in the TP53 pathway and apoptosis regulators in metastases.</p><p><strong>Conclusion: </strong>Primary and metastatic lesions of bladder urothelial carcinoma show broadly similar gene- and pathway-level alteration profiles on targeted DNA sequencing. TP53 pathway and apoptosis-related alterations are modestly more frequent in metastases, consistent with impaired stress responses and apoptosis evasion.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"868-877"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head and neck cancer of unknown primary: a nationwide analysis of hospital-based cancer registry data in Japan, 2018-2022.","authors":"Ryoko Rikitake, Yu Mizushima, Toshihiko Sakai, Takahiro Higashi","doi":"10.1007/s10147-026-02984-6","DOIUrl":"10.1007/s10147-026-02984-6","url":null,"abstract":"<p><strong>Background: </strong>Some head and neck cancers are metastatic tumors of unknown primary origin, but their epidemiology has seldom been studied. This study aimed to address this knowledge gap using a nationwide database in Japan. Furthermore, we examined the nationwide implementation of human papillomavirus (HPV) and Epstein-Barr virus (EBV) testing, assessed their inter-facility and temporal variations, and compared these findings with oropharyngeal cancer cases.</p><p><strong>Methods: </strong>Head and neck squamous cell carcinoma of unknown primary origin and oropharyngeal squamous cell carcinoma diagnosed between 2018 and 2022 were identified from the Hospital-based Cancer Registries of Japan. Data on sex, age, TNM classification, HPV and EBV test results, and treatment facilities were collected. Temporal changes in viral diagnostic practices were analyzed.</p><p><strong>Results: </strong>We identified 1636 new cases of head and neck cancers of unknown primary. The disease was more common in males and patients aged 70-74 years. HPV positivity was more frequent in patients aged 45-59 years, whereas EBV positivity was less frequent in all age groups. Of the patients, 67.6% were treated at certified head and neck cancer facilities, which had higher viral testing rates than non-certified facilities. Case numbers remained stable over time, whereas viral testing and HPV positivity increased; however, both remained lower than in oropharyngeal cancer cases.</p><p><strong>Conclusions: </strong>This study visualized real-world virus testing for patients with head and neck cancers of unknown primary, providing insights into diagnostic equity, institutional capacity, and the need for standardized cancer care. Continued surveillance is essential to improve outcomes in this rare condition.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"775-784"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a predictive model for pleural effusion control following talc pleurodesis in malignant pleural effusion.","authors":"Shunya Hanawa, Masaru Ejima, Mari Sugawara, Natsushi Kubota, Rina Kato, Kotaro Hanawa, Seishi Higashi, Satoko Hanada, Reiko Taki","doi":"10.1007/s10147-026-03007-0","DOIUrl":"10.1007/s10147-026-03007-0","url":null,"abstract":"<p><strong>Background: </strong>Talc slurry pleurodesis is widely used for malignant pleural effusion (MPE); however, its success rate ranges from 50 to 75%, and reliable predictors are lacking. This study aimed to identify predictors of pleural effusion control failure following pleurodesis and develop a short-term predictive scoring system.</p><p><strong>Methods: </strong>We retrospectively analyzed 170 patients with MPE who underwent talc pleurodesis at a single center between 2014 and 2024. The cohort was divided into training (n = 136) and validation (n = 34) cohorts. Logistic regression was used to identify independent predictors of pleural effusion control failure within 30-90 days.</p><p><strong>Results: </strong>The most common primary tumors were lung, breast, and ovarian cancers. Pleural effusion was controlled in 70.6% of cases. Univariate analysis identified low body mass index, supportive care alone, Grade 2 collapse of the lower lung field post-drainage, extensive pulmonary consolidation, large tumor (≥ 7 cm), hypoalbuminemia, and positive pleural fluid cytology (Class III or higher) to be associated with pleural effusion control failure. Multivariate analysis revealed that massive pleural effusion (P = 0.048), supportive care alone (P < 0.001), and Grade 2 lung collapse (P = 0.003) were independent predictors of pleural effusion control failure. A scoring system incorporating these factors was validated in a validation cohort, demonstrating a control rate of approximately 90%, 60% and 30% in patients scoring ≤ 1, 2 and ≥ 3 points, respectively.</p><p><strong>Conclusions: </strong>The scoring system may support early decision-making regarding talc pleurodesis and palliative strategies, potentially improving quality of life in patients with MPE.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"890-898"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147473170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical application value of body composition in predicting the prognosis of rectal cancer.","authors":"Yongpeng Ouyang, Ding Li, Binsong Xia, Kunjian Xia","doi":"10.1007/s10147-026-03015-0","DOIUrl":"10.1007/s10147-026-03015-0","url":null,"abstract":"<p><strong>Background: </strong>While computed tomography (CT)-based body composition has been studied for prognostic prediction in colorectal cancer, specific analyses for rectal cancer patients remain limited. This study aimed to investigate the relationship between CT-derived body composition indices and long-term postoperative outcomes in rectal cancer patients and to develop corresponding predictive models.</p><p><strong>Methods: </strong>In this multicenter retrospective study, 696 patients who underwent radical surgery for rectal cancer between 2018 and 2021 were enrolled. Skeletal muscle index (SMI) and subcutaneous adipose tissue index (SATI) were calculated from preoperative CT scans at the third lumbar vertebra. Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors for recurrence-free survival (RFS) and overall survival (OS). Nomogram prediction models were constructed based on significant factors and validated internally using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>A total of 96 (13.8%) patients experienced recurrence and 89 (12.8%) died during follow-up. Multivariate analysis identified low SMI and high SATI as independent predictors of both poorer RFS (SMI: HR = 0.329, 95% CI 0.182-0.595; SATI: HR = 2.717, 95% CI 1.505-4.905) and OS (SMI: HR = 0.132, 95% CI 0.053-0.330; SATI: HR = 3.542, 95% CI 1.739-7.211), along with advanced T and N stages.Query The developed nomograms demonstrated good predictive accuracy. For RFS prediction, the area under the curve (AUC) values were 0.862, 0.846, and 0.824 for 3-, 4-, and 5-year predictions in the training set, and 0.825, 0.866, and 0.838 in the validation set. For OS prediction, the AUCs were 0.886, 0.898, and 0.875 (training set), and 0.876, 0.912, and 0.877 (validation set). Calibration curves and DCA indicated favorable model performance and clinical utility.</p><p><strong>Conclusion: </strong>CT-derived body composition, specifically SMI and SATI, is associated with postoperative RFS and OS in rectal cancer patients. The established nomograms, integrating these indices with tumor stage, provide a valuable and individualized tool for prognostic assessment.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"915-927"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147490848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of the modified Glasgow Prognostic Score and Prognostic Nutritional Index in prostate cancer treated with cabazitaxel.","authors":"Takuma Kato, Yoichiro Tohi, Atsushi Takamoto, Ryutaro Shimizu, Kei Daizumoto, Satoshi Katayama, Keita Kobayashi, Hirofumi Morinaka, Kenichi Nishimura, Hideo Fukuhara, Shuichi Morizane, Junya Furukawa, Motoo Araki, Koji Shiraishi, Yoshiyuki Miyaji, Noriyoshi Miura, Keiji Inoue, Mikio Sugimoto","doi":"10.1007/s10147-026-02996-2","DOIUrl":"10.1007/s10147-026-02996-2","url":null,"abstract":"<p><strong>Background: </strong>The modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are useful prognostic indicators in various cancer types. This study assessed the utility of the mGPS and PNI in predicting survival in men with castration-resistant prostate cancer treated with cabazitaxel.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed data on patients who received cabazitaxel for castration-resistant prostate cancer between September 2014 and March 2022. The mGPS was scored on a scale of 0-2 points based on the albumin and C-reactive protein (CRP) levels. PNI was calculated using the albumin level and lymphocyte count. The effect of the mGPS and PNI on survival was assessed using the log-rank test and Cox regression.</p><p><strong>Results: </strong>A total of 215 patients were included in the analysis, of whom 103 (47.9%), 64 (29.8%), and 48 (22.3%) had an mGPS of 0, 1, and 2 points, respectively. The median PNI was 42.2 (interquartile range [IQR]: 38.8-45.9). In a risk model using hemoglobin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and mGPS, the median survival was 19, 13, and 5 months in the low-, intermediate-, and high-risk groups, respectively. In a risk model using ALP, LDH, and PNI, the overall survival was 18, 13, and 5 months in the low-, intermediate-, and high-risk groups, respectively.</p><p><strong>Conclusion: </strong>The mGPS and PNI are useful prognostic indicators for risk stratification to predict survival in patients with castration-resistant prostate cancer treated with cabazitaxel.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"834-842"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147511588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive circulating tumor DNA mutation profiling via CAPP-Seq liquid biopsy for cervical cancer.","authors":"Naoyuki Iwahashi, Tomoko Noguchi, Kazuko Sakai, Tamaki Yahata, Kaho Nishioka, Megumi Fujino, Shinichiro Takeda, Nobuhiko Suzuki, Kazuto Nishio, Kazuhiko Ino","doi":"10.1007/s10147-026-03006-1","DOIUrl":"10.1007/s10147-026-03006-1","url":null,"abstract":"<p><strong>Background: </strong>Liquid biopsy using circulating tumor DNA (ctDNA) is a minimally invasive approach for detecting tumor-associated genomic alterations. Although ctDNA analysis has been widely explored in solid tumors, its application to cervical cancer remains limited. Cancer personalized profiling by deep sequencing (CAPP-Seq) enables sensitive ctDNA profiling via molecular barcoding and digital error suppression.</p><p><strong>Methods: </strong>We evaluated the feasibility of ctDNA-based mutation profiling in cervical cancer using the CAPP-Seq platform by analyzing plasma samples from 38 patients.</p><p><strong>Results: </strong>The cohort included three patients with stage I disease, nine with stage II, 19 with stage III, and seven with stage IV. Somatic gene alterations were detected in 33 of the 38 cases (87%), including squamous cell carcinoma (27/29 [93%]) and adenocarcinoma (6/9 [67%]). Non-synonymous mutations were identified in 23 patients (59%), with PIK3CA being the most frequently mutated gene [13/38 (34%)]. Copy number gains of EGFR, MET, and ERBB2 were observed in 24%, 11%, and 5% of cases, respectively. The median blood tumor mutational burden was 17.7 mutations/Mb, and 50% of the patients exhibited a hypermutated phenotype. In a subset of four patients who received concurrent chemoradiotherapy, longitudinal changes in ctDNA mutation profiles between pre- and post-treatment samples were associated with treatment response.</p><p><strong>Conclusions: </strong>This study demonstrates the feasibility of ctDNA-based mutation profiling using CAPP-Seq in cervical cancer, with a high detection rate of tumor-associated genomic alterations across histological subtypes. ctDNA analysis may represent a minimally invasive approach for the molecular characterization and disease monitoring of cervical cancer.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"878-889"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147432844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}